Spots Global Cancer Trial Database for Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
Official Title: The Neoantigen Targeting T Cells Suspension for Intravenous Infusion(Neo-T) in Treating Patients With Advanced Solid Tumor
Study ID: NCT05798533
Conditions
Study Description
Brief Summary: The primary objective of this study is to evaluate the safety of Neo-T in combination with anti-PD1 in patients with solid tumors. The secondary objective of this study is to evaluate preliminarily the effect of Neo-T in combination with anti-PD1 in patients with solid tumors.
Detailed Description: This is a single arm, open label and non-randomized clinical study. 6 to12 patients will be enrolled to assess the safety and explore recommended dose of Neo-T combined with anti-PD1.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fudan University Shanghai Cancer Center, Shanghai, , China
Shanghai Tenth People's Hospital, Shanghai, , China
Contact Details
Name: Jian Zhang, Doctor
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Name: Yong Chen, Doctor
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Name: Qing Xu, Doctor
Affiliation: Shanghai 10th People's Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
